Clinical Trial Update: 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 randomized trial comparing rosiglitazone with glimepiride in type 2 diabetes, assessing 24-hour glycemic control. The results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glimepiride (glimepiride)
• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Non-Insulin-Dependent Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2009-03-18